A More Direct Liquefaction of Bronchial Secretion by Aerosol Therapy

Abstract

SUMMARY AND CONCLUSIONS 1. Aerosol therapy is indicated when thick viscous mucopurulent secretion occurs in bronchopulmonary disease. 2. Its action and limitations in such cases is discussed, including the need of a liquefying aerosol. 3. In severe and chronic disease, an aerosol containing liquid, detergent and a mucolytic chemical is the efficient approach. 4. A new aerosol solution containing Tergitol 08 (sodium 2-hexylethyl sulfate) 0.125 per cent, potassium iodide 0.1 per cent in water is described. 5. A series of 96 patients with severe bronchopulmonary disease was treated by this aerosol solution. No irritation of mucous membranes or toxicity was noted. 6. Clinical results are reported: Excellent in 66, good in 30, fair none, no improvement, none. 7. This aerosol solution appears to be definitely beneficial in bronchopulmonary disease with thick viscous mucopurulent secretion.